DSCSA Compliance - Mpje

1. A pharmacy receives a shipment of prescription drug products without any T3 documentation. Which of the following is the appropriate action?
   Answer: The pharmacy must quarantine the shipment until complete T3 documentation is obtained. T3 documentation must accompany each prescription drug product transfer. Accepting and dispensing products without T3 documentation is a DSCSA violation. A correctly identifies the required response. B is incorrect because a 30-day grace period for obtaining T3 is not provided by DSCSA. C is incorrect because DSCSA applies to all prescription drug products, not only controlled substances. D is incorrect because distributor licensure alone does not satisfy the T3 documentation requirement.
2. DSCSA requires trading partners to have systems and processes in place to respond to FDA requests for verification of product identifiers. What does this mean for a pharmacy in practice?
   Answer: Pharmacies must verify product identifiers upon FDA request and respond within specified timeframes. DSCSA requires pharmacies to have the capability to verify product identifiers when triggered by an FDA request or a suspect product investigation, and to respond within FDA-specified timeframes. This is a targeted verification capability, not a universal dispense-time scanning requirement. D correctly describes this obligation. A is incorrect because routine verification of every dispensed unit is not required for pharmacies under current DSCSA dispenser requirements. B is incorrect because monthly FDA verification reports are not required. C is incorrect because FDA-certified equipment is not a specified requirement.
3. Which of the following correctly describes the difference between a suspect product and an illegitimate product under DSCSA?
   Answer: A suspect product is unconfirmed; an illegitimate product is confirmed counterfeit, diverted, stolen, or adulterated. DSCSA draws a clear distinction: suspect products are those reasonably believed to potentially have supply chain integrity problems but not yet confirmed; illegitimate products are those confirmed to have such problems. Different obligations apply to each status, with illegitimate products triggering mandatory FDA notification. A correctly identifies this distinction. B is incorrect because the two terms have different definitions and trigger different obligations. C is incorrect because FDA notification is required for illegitimate products, not suspect products. D is incorrect because suspect products require quarantine and investigation, not destruction, and illegitimate products must not be dispensed.
4. What is the Transaction Statement (TS) in the context of DSCSA T3 documentation?
   Answer: A certification of authorized trading partner product compliance. The Transaction Statement is the trading partner's written attestation that the product was received from authorized trading partners, is not suspect or illegitimate, has not been detained or recalled, is not a counterfeit, and was handled in compliance with DSCSA. A correctly identifies this certification function. B is incorrect because the TS is a private trading partner certification, not a government-issued document. C is incorrect because a dispensing label is not a T3 document. D is incorrect because FDA inspection reports are separate regulatory documents.
5. A pharmacy receives a suspect product notification from a trading partner about a lot of an antihypertensive it currently has in stock. The pharmacy has not yet dispensed any units. What is the pharmacy's first required action under DSCSA?
   Answer: Quarantine the identified lot immediately to prevent dispensing while conducting a DSCSA investigation with the trading partner. Upon receiving a suspect product notification, the pharmacy's first required action is to quarantine all units of the identified lot to prevent dispensing while the investigation proceeds. B correctly identifies this immediate obligation. A is incorrect because dispensing after receiving a suspect notification is a serious DSCSA violation. C is incorrect because product return before completing the investigation would eliminate the ability to fulfill DSCSA investigation requirements. D is incorrect because state board notification is not the first required DSCSA action; quarantine and investigation are.
6. A pharmacy chain uses a centralized electronic system for supply chain transaction records (transaction information and transaction statements) maintained at corporate headquarters. During a state board inspection of an individual branch, the inspector requests these records. The branch cannot access the corporate system due to a system outage. Which of the following best analyzes the compliance concern?
   Answer: There is a compliance concern due to inaccessible transaction records during inspection at the branch location. DSCSA requires that each dispensing location be able to produce its supply chain transaction records -- transaction information and transaction statements -- upon inspection. A centralized system that is inaccessible at the branch level during an inspection fails this accessibility requirement regardless of the cause. The pharmacy must implement redundancy or contingency measures to ensure records are accessible at each registered location. C correctly identifies the compliance concern. A is incorrect because corporate-level maintenance does not satisfy the branch-level accessibility requirement. B is incorrect because a systemic failure to ensure record accessibility at each location is not excused by force majeure principles; the accessibility obligation is ongoing. D is incorrect because requiring the inspector to contact a third party is not an acceptable substitute for branch-level record production.
7. A pharmacist in a hospital notices that a surgical supply vendor has left a box of fentanyl patches in a medication preparation area. The box has no T3 documentation. Which of the following best applies from a DSCSA and DEA perspective?
   Answer: The pharmacist must reject the patches; fentanyl requires DSCSA transaction documentation and DEA compliance, and the vendor is unauthorized. This scenario presents dual compliance concerns: DSCSA requires transaction information and a transaction statement from an authorized trading partner for prescription drugs, and DEA regulations impose strict chain-of-custody and ordering requirements for Schedule II controlled substances. A surgical supply vendor is not an authorized DSCSA trading partner for prescription drug distribution, and the absence of proper documentation for a Schedule II controlled substance creates a serious DEA compliance concern as well. D correctly identifies both issues. A is incorrect because surgical supply vendors are not authorized DSCSA trading partners for prescription drugs regardless of any other authorization. B is incorrect because retroactive documentation does not cure an unauthorized transaction or an improperly sourced Schedule II. C is incorrect because verbal assurances do not substitute for required supply chain documentation and DEA compliance.
8. Under DSCSA, what constitutes the 'product identifier' that must be placed on certain prescription drug packages?
   Answer: A 2D barcode with NDC, serial, lot, and expiration date. DSCSA requires a standardized product identifier on drug packages encoding the NDC, a unique serial number, lot number, and expiration date -- typically in a 2D data matrix barcode format. D correctly identifies these required elements. A is incorrect because the NDC in human-readable text alone does not constitute the full DSCSA product identifier. B is incorrect because lot number alone is insufficient. C is incorrect because manufacturer identification alone does not constitute the product identifier.
9. A pharmacy receives a drug shipment and verifies that the T3 documents are complete. The physical packaging of some units shows a slight color variation from what the pharmacist expects. Which of the following best describes the appropriate response?
   Answer: Quarantine affected units and investigate color variation for potential suspect product. Document findings. Complete T3 documentation satisfies the paperwork requirement, but pharmacists also have an obligation to identify suspect products based on physical indicators. Color variation is a potential indicator of counterfeiting requiring quarantine and investigation of affected units. B correctly balances these obligations. A is incorrect because T3 compliance does not override the obligation to investigate physical indicators of suspect product. C is incorrect because returning the entire shipment without investigation and documentation does not satisfy DSCSA requirements. D is incorrect because dismissing color variation as normal without investigation may miss a genuine counterfeiting indicator.
10. Under DSCSA, a pharmacy that is transferring ownership of its prescription drug inventory to a new pharmacy must provide which of the following to the receiving pharmacy?
    Answer: Transaction information and statement for all transferred prescription drugs. When prescription drug products are transferred between pharmacies, the transferring pharmacy must provide transaction information and a transaction statement -- the currently required DSCSA supply chain documentation -- for all products being transferred. The receiving pharmacy must maintain these records for the required retention period. C correctly identifies this requirement. A is incorrect because a bill of sale alone does not constitute DSCSA-compliant supply chain documentation. B is incorrect because the DEA registration number alone is not sufficient supply chain documentation. D is incorrect because a condition attestation does not satisfy DSCSA requirements.
11. Under DSCSA, how must a pharmacy produce supply chain transaction records when requested by the FDA during an inspection?
    Answer: The pharmacy must provide transaction records in an accessible format, including electronic, per FDA's request timeline. DSCSA requires pharmacies to maintain and be able to produce supply chain transaction records -- currently transaction information and transaction statement under the enhanced tracing framework -- in a reasonably accessible format, including electronic records, for the 6-year retention period and upon FDA request during inspections. A correctly identifies this production obligation. B is incorrect because electronic records are acceptable and in fact standard under the enhanced tracing framework. C is incorrect because the pharmacy itself must maintain and produce its own records; distributor records are separate. D is incorrect because a 30-day production window is inconsistent with FDA's inspection authority; records must be accessible and producible upon request.
12. A pharmacy's DSCSA investigation determines a product is illegitimate. Within what timeframe must the pharmacy notify the FDA?
    Answer: Within 24 hours of making the determination that the product is illegitimate. DSCSA requires that the FDA be notified within 24 hours of a determination that a product is illegitimate -- meaning confirmed to be counterfeit, diverted, stolen, or intentionally adulterated. B correctly states this timeframe. A is incorrect because the 24-hour clock runs from the illegitimacy determination, not from quarantine placement. C is incorrect because 30 days far exceeds the 24-hour requirement. D is incorrect because FDA notification is mandatory upon confirmation of illegitimacy.
13. A pharmacy's DSCSA investigation cannot verify a product's legitimacy because the trading partner is unresponsive to investigation requests over a two-week period. What must the pharmacy do?
    Answer: Maintain quarantine and notify the FDA and trading partners of the verification issue. When a pharmacy cannot verify a product's legitimacy after reasonable investigation efforts -- including an unresponsive trading partner -- DSCSA requires maintaining the quarantine and escalating to the FDA and affected trading partners. Inability to verify legitimacy is not a legal determination that the product is illegitimate, but it is sufficient reason to keep the product out of the supply chain until legitimacy can be established. B correctly identifies this risk-based approach. A is incorrect because passage of time alone does not authorize release from quarantine; the legitimacy question must be resolved. C is incorrect because dispensing a product with unresolved legitimacy concerns violates DSCSA. D is incorrect because state board notification is not the required DSCSA response; FDA and trading partner escalation is the applicable framework.
14. DSCSA requires pharmacies to be able to trace a prescription drug product through the supply chain. What does this tracing capability require a pharmacy to do in practice?
    Answer: Keep T3 records to trace drug products back through the supply chain when requested. DSCSA tracing capability requires pharmacies to maintain T3 records that can be produced for FDA review or for suspect/illegitimate product investigations, enabling reconstruction of the product's supply chain path. D correctly describes this practical requirement. A is incorrect because GPS tracking is not a DSCSA requirement. B is incorrect because physical examination of every product is not a DSCSA-mandated tracing requirement. C is incorrect because real-time location reporting to the FDA is not required under DSCSA.
15. What information must be included in the Transaction Information (TI) under DSCSA?
    Answer: Drug name, strength, dosage form, NDC, lot number, transaction and shipment dates. DSCSA requires Transaction Information to include specific product identification details -- name, strength, dosage form, NDC number, container size, number of containers, lot number -- along with transaction and shipment dates, and the business name and address of both the transferring party and the receiving party. C correctly identifies these comprehensive requirements. A is incorrect because drug name and lot number alone are far below the required TI content. B is incorrect because manufacturer name and DEA number alone do not satisfy TI requirements. D is incorrect because transaction date and NDC number alone are also insufficient.
16. Under DSCSA's current enhanced drug tracing requirements, which documents must accompany each transfer of a prescription drug product through the supply chain?
    Answer: Transaction information (TI) and transaction statement (TS) are required. Under DSCSA's enhanced drug tracing requirements that took effect November 27, 2023, each transfer of a prescription drug product must be accompanied by transaction information and a transaction statement. The requirement to provide and receive transaction history ended on November 27, 2023, when the enhanced interoperable electronic tracing system replaced the legacy T3 framework. A correctly identifies the current documentation standard. B is incorrect because receipt, invoice, and confirmation are not DSCSA-designated documents. C is incorrect because it describes the former T3 framework, including transaction history, which is no longer required under the current enhanced tracing standard. D is incorrect because these are not DSCSA-defined document categories.
17. Which federal law established the Drug Supply Chain Security Act (DSCSA) framework for tracking and tracing prescription drug products through the supply chain?
    Answer: The Drug Quality and Security Act of 2013, Title II of which is the DSCSA. The DSCSA was enacted as Title II of the Drug Quality and Security Act (DQSA) of 2013. B correctly and precisely identifies this. A is incorrect because the Controlled Substances Act governs controlled substance regulation, not drug supply chain security. C is incorrect because DSCSA was not enacted as standalone independent legislation; it is Title II of the DQSA. D is incorrect because the 2007 FDCA amendments addressed different topics and predated the DSCSA.
18. A pharmacy receives a salesperson's offer to sell branded prescription drug products directly from a manufacturer's representative at a significant discount, bypassing the usual wholesale distributor. Which of the following best analyzes this offer from a DSCSA perspective?
    Answer: The pharmacy must verify the manufacturer's authorized trading partner status and obtain required transaction documentation. While manufacturers are authorized trading partners, the specific transaction must still be conducted through authorized channels with the required supply chain documentation -- transaction information and a transaction statement under the current DSCSA enhanced tracing framework. A salesperson conducting an informal direct sale may not represent an authorized transaction channel even if the manufacturer is registered. D correctly identifies the compliance analysis required. A is not fully correct because manufacturer registration does not automatically authorize every sales representative's transaction channel. B is incorrect because a salesperson's signed statement does not satisfy DSCSA documentation requirements. C is incorrect because expiration date does not substitute for required documentation and authorized trading partner verification.
19. A pharmacy purchases a prescription drug product from a source that provides transaction information and a transaction statement but is not an FDA-registered establishment. Which of the following best describes the DSCSA compliance concern?
    Answer: Purchasing from a non-authorized trading partner violates DSCSA, regardless of transaction documentation provided. DSCSA requires transactions with authorized trading partners -- entities that are appropriately licensed or registered. Receiving transaction documentation from an unauthorized source does not cure the fundamental DSCSA requirement for authorized trading partners. A correctly identifies this compliance concern. B is incorrect because transaction documentation alone does not satisfy the authorized trading partner requirement. C is incorrect because post-dispensing FDA contact does not resolve a transaction with an unauthorized trading partner. D is incorrect because authorization status is independent of the documentation received.
20. Under DSCSA's product verification requirements, which of the following represents an obligation for pharmacies when dispensing prescription drug products?
    Answer: Pharmacies must verify product identifiers for suspect products or when directed by the FDA. DSCSA's verification requirements for dispensers are triggered by suspect product identification or FDA/trading partner direction, not routine unit-level verification of every dispensed product. Routine verification is not required for standard dispensing operations at the pharmacy level. C correctly describes this targeted rather than universal verification obligation. A is incorrect because routine 2D barcode verification of every dispensed unit is not required under current DSCSA dispenser requirements. B is incorrect because dispensing reports to the FDA are not required for every product. D is incorrect because manufacturer verification is not required for every controlled substance dispensed.

Start this quiz